Related Experiment Video

Updated: Feb 6, 2026

Synergizing Antegrade Endoscopic with Bridging Vein Harvesting for Improvement of Great Saphenous Vein Graft Quality from the Lower Leg
09:04

Synergizing Antegrade Endoscopic with Bridging Vein Harvesting for Improvement of Great Saphenous Vein Graft Quality from the Lower Leg

Published on: November 19, 2019

9.2K

Application of Endoscopic Vein Harvesting in Obese Patients Undergoing Coronary Artery Bypass Grafting

Peng Bai1, Yi-Xuan Wang1, Si Chen1

  • 1Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Current Medical Science
|August 22, 2018
PubMed

Insights

Endoscopic vein harvesting (EVH) for coronary artery bypass grafting (CABG) in obese patients significantly reduces harvesting time and wound complications. EVH is a reliable option, showing no adverse impact on short- to medium-term clinical outcomes.

Area of Science:

  • Cardiovascular Surgery
  • Minimally Invasive Techniques
  • Obesity Medicine

Background:

  • Coronary artery bypass grafting (CABG) is a common procedure for coronary artery disease.
  • Obesity presents unique challenges in CABG, particularly regarding surgical access and wound healing.
  • Endoscopic vein harvesting (EVH) offers a minimally invasive alternative to traditional vein harvesting techniques.

Purpose of the Study:

  • To evaluate the clinical outcomes of EVH compared to standard bridging technique (SBT) in obese patients undergoing CABG.
  • To assess the impact of EVH on operative parameters, postoperative complications, and short- to medium-term results in this specific patient population.

Main Methods:

  • Retrospective, non-randomized controlled study involving 153 obese patients undergoing CABG.
  • Patients were divided into two groups: EVH (n=81) and SBT (n=12).
  • Analysis included operation time, vessel damage, revascularization rates, vessel dysfunction, mortality, harvesting time, incision length, and lower extremity complications.

Main Results:

  • No significant differences were observed in total operation time, vessel damage, revascularization rates, vessel dysfunction, or mortality between EVH and SBT groups.
  • EVH demonstrated a significant reduction in total vein harvesting time (41±6 min vs. 63±11 min) and incision length (4.4±1.1 cm vs. 18.2±4.5 cm).
  • EVH was associated with a significant decrease in postoperative lower extremity wound complications.

Conclusions:

  • Endoscopic vein harvesting (EVH) is a safe and effective method for conduit procurement in obese patients undergoing CABG.
  • EVH significantly reduces wound complications and harvesting time without compromising short- and medium-term clinical outcomes.
  • EVH can be considered a reliable and advantageous procedure for obese patients requiring CABG.

Keywords:
coronary artery bypass graftingminimally invasive endoscopyobesitysaphenous vein harvesting

More Related Videos

Author Spotlight: Enhancing Coronary Artery Revascularization05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.3K
Vein Interposition Model: A Suitable Model to Study Bypass Graft Patency07:22

Vein Interposition Model: A Suitable Model to Study Bypass Graft Patency

Published on: January 15, 2017

9.3K

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
268
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.1K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
492
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
283
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
286
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
191